AbbVie (ABBV) Stock Forecast & Price Target $285.66 +0.47 (+0.16%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$285.27 -0.39 (-0.14%) As of 10/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest AbbVie - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 30 Analyst RatingsSell0Hold6Buy24 Based on 30 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 6 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for ABBV. Consensus Price Target $279.86-2.03% Downside According to the 30 analysts' twelve-month price targets for AbbVie, the average price target is $279.86. The highest price target for ABBV is $325.00, while the lowest price target for ABBV is $225.00. The average price target represents a forecasted downside of -2.03% from the current price of $285.66. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy1 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)0 Strong Buy rating(s)Buy23 Buy rating(s)23 Buy rating(s)18 Buy rating(s)16 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)7 Hold rating(s)9 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$279.86$272.66$265.96$236.19Forecasted Upside-2.03% Downside3.10% Upside3.49% Upside3.57% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ABBV Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ABBV Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table AbbVie Stock vs. The CompetitionTypeAbbVieHealthcare CompaniesBroader MarketConsensus Rating Score 2.83 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside-2.03% Downside1,400.11% Upside16.92% UpsideNews Sentiment RatingPositive NewsSee Recent ABBV NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/23/2026 The Goldman Sachs Group3 of 5 starsAsad Haider5 of 5 starsBoost TargetNeutral$258.00 ➝ $294.00+3.31%10/21/2026 Barclays3 of 5 starsEmily FieldNot RatedBoost TargetOverweight$300.00 ➝ $325.00+12.59%10/13/2026 Royal Bank Of Canada2 of 5 starsTrung HuynhNot RatedReiterated RatingOutperform$280.00+0.58%10/9/2026 GuggenheimSubscribe to MarketBeat All Access to unlock brokerage rankingsVamil DivanSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$288.00+4.85%10/8/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeBuy (B-) ➝ Buy (B)10/8/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsChris SchottSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$285.00 ➝ $300.00+10.21%10/8/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankingsCarter GouldSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$285.00 ➝ $290.00+6.87%10/7/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsTerence FlynnSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$296.00 ➝ $310.00+14.10%10/6/2026 ScotiabankSubscribe to MarketBeat All Access to unlock brokerage rankingsLouise ChenSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$280.00 ➝ $320.00+21.56%10/6/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael YeeSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetNeutral$260.00 ➝ $275.00+4.47% Get the Latest News and Ratings for ABBV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. 9/10/2026 HSBCSubscribe to MarketBeat All Access to unlock brokerage rankingsRajesh KumarSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$300.00 ➝ $315.00+25.48%9/8/2026 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankingsGeoff MeachamSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy8/20/2026 Piper SandlerSubscribe to MarketBeat All Access to unlock brokerage rankingsDavid AmsellemSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$298.00 ➝ $303.00+14.07%8/17/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsMohit BansalSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$295.00 ➝ $300.00+20.38%8/13/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsAlexandria HammondSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradePeer Perform ➝ Outperform$235.00 ➝ $300.00+20.42%8/11/2026 BNP Paribas ExaneSubscribe to MarketBeat All Access to unlock brokerage rankingsNavann TySubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetNeutral$218.00 ➝ $247.00-1.15%8/5/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetOutperform$245.00 ➝ $279.00+4.74%8/5/2026 Erste Group BankSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeHold ➝ Buy8/4/2026 Rothschild & Co RedburnSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$284.00 ➝ $285.00+6.99%8/4/2026 ArgusSubscribe to MarketBeat All Access to unlock brokerage rankings Boost Target$250.00 ➝ $270.00+1.36%8/3/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsGary NachmanSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$282.00 ➝ $290.00+15.39%8/3/2026 OppenheimerSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetNeutral$244.00 ➝ $258.00-3.15%7/15/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsGeoff MeachamSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetNeutral$230.00 ➝ $260.00+6.23%7/13/2026 BMO Capital MarketsSubscribe to MarketBeat All Access to unlock brokerage rankingsEvan David SeigermanSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$258.00 ➝ $300.00+20.97%6/23/2026 Sanford C. BernsteinSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingMarket Perform$203.00 ➝ $225.00-4.00%5/15/2026 EvercoreSubscribe to MarketBeat All Access to unlock brokerage rankings Set TargetOutperform$236.00 ➝ $235.00+10.71%5/5/2026 Daiwa Securities GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Lower TargetOutperform$244.00 ➝ $237.00-11.09%4/30/2026 DZ BankSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeHold ➝ Strong-Buy3/9/2026 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOutperform1/20/2026 Berenberg BankSubscribe to MarketBeat All Access to unlock brokerage rankingsLuisa HectorSubscribe to MarketBeat All Access to unlock analyst rankingsSet TargetBuy$270.00 ➝ $275.00+28.28%11/3/2025 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsGary NachmanSubscribe to MarketBeat All Access to unlock analyst rankingsSet TargetOutperform$250.00 ➝ $256.00+17.36%10/3/2025 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$250.00 ➝ $280.00+5.12%9/15/2025 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetHold$173.00 ➝ $204.00-23.41%2/3/2025 Truist FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsSrikripa DevarakondaSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$211.00 ➝ $217.00+14.50%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:26 PM ET. Should I Buy AbbVie Stock? ABBV Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com. AbbVie Bull Case Here are some ways that investors could benefit from investing in AbbVie: AbbVie received FDA approval on October 23, 2026, for a subcutaneous induction regimen for SKYRIZI in Crohn's disease, a significant expansion that supports early symptomatic control and strengthens the company's immunology portfolio against competitors. The stock is currently trading at $285.66, which is near its 52-week high of $291.40, reflecting strong recent momentum and a consensus rating of Moderate Buy with a price target of $278.07, indicating analyst confidence in the company's trajectory. AbbVie reported Q2 2026 revenue of $16.99 billion, beating estimates of $16.80 billion and growing 10.2% year-over-year, demonstrating robust commercial execution and demand for its key products like Skyrizi and Rinvoq. The company offers a dividend yield of 2.43% with a recent quarterly payout of $1.73 per share, providing a steady income stream for investors, supported by a long history of dividend increases and a payout ratio that remains manageable relative to its earnings power. AbbVie's lutikizumab met its primary endpoint in the Phase 3 INTREPID trial for hidradenitis suppurativa, adding a new potential revenue driver in the immunology space and diversifying the company's pipeline beyond its core franchises. AbbVie Bear Case Investors should be bearish about investing in AbbVie for these reasons: Analysts have recently lowered earnings forecasts, with Erste Group Bank reducing its FY2026 EPS estimate to $13.90 from $14.00, and the consensus estimate for full-year earnings has dropped to $13.94, signaling potential pressure on profitability. The stock trades at a P/E ratio of 80.69, which is significantly high and suggests that the market is pricing in substantial future growth, leaving little room for error if earnings disappoint or if the company faces patent cliff challenges. AbbVie halted an early-stage liver cancer combination trial, a setback in its oncology pipeline that may limit near-term growth opportunities in that therapeutic area and raise questions about the success rate of its newer drug candidates. Despite meeting trial endpoints, the efficacy of lutikizumab in the INTREPID trial was characterized by some analysts as below expectations, with the advantage over placebo viewed as underwhelming, which could limit its commercial impact and competitive positioning. Institutional investors have been reducing their stakes, with funds like Vest Financial LLC and Investment House LLC significantly cutting their positions in the third quarter, indicating a lack of confidence from large holders in the stock's near-term performance. ABBV Forecast - Frequently Asked Questions What is AbbVie's forecast for 2026? According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $279.86, with a high forecast of $325.00 and a low forecast of $225.00. Should I buy or sell AbbVie stock right now? 30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares. Does AbbVie's stock price have much downside? According to analysts, AbbVie's stock has a predicted downside of -2.03% based on their 12-month stock forecasts. Has AbbVie been upgraded by Wall Street analysts recently? Over the previous 90 days, AbbVie's stock had 4 upgrades by analysts. What analysts cover AbbVie? AbbVie has been rated by research analysts at Argus, Bank of America, Barclays, BNP Paribas Exane, Canaccord Genuity Group, Cantor Fitzgerald, Erste Group Bank, Guggenheim, HSBC, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Oppenheimer, Piper Sandler, Rothschild & Co Redburn, Royal Bank Of Canada, Scotiabank, The Goldman Sachs Group, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days. Do Wall Street analysts like AbbVie more than its competitors? Analysts like AbbVie more than other "healthcare" companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABBV compares to other companies. Stock Forecasts and Research Tools Related Companies Amgen Stock Forecast Gilead Sciences Stock Forecast Moderna Stock Forecast Abbott Laboratories Stock Forecast Astrazeneca Stock Forecast Bristol Myers Squibb Stock Forecast Johnson & Johnson Stock Forecast Eli Lilly and Company Stock Forecast Merck & Co., Inc. Stock Forecast Pfizer Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With AbbVie RecommendationsThe Goldman Sachs GroupBarclaysRoyal Bank Of CanadaGuggenheimCantor FitzgeraldJPMorgan Chase & Co.Weiss RatingsMorgan StanleyUBS GroupScotiabankHSBCBank of AmericaPiper SandlerWells Fargo & CompanyWolfe Research MarketBeat monitors more than a dozen sources for AbbVie analyst ratings, with the most recent rating issued on 10/23/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.